Core Insights - Aytu BioPharma reported net revenue of $15.2 million for Q2 2026, with ADHD portfolio revenue at $13.2 million, reflecting a slight decrease due to a strategic shift towards launching EXUA, the first FDA-approved 5HT1A agonist for treating major depressive disorder (MDD) [12][18] - The commercial launch of EXUA is supported by a targeted marketing strategy, including a strong sales team and the RX Connect platform to ensure patient access and minimize costs [13][19] - Management emphasized a cautious approach towards expanding the salesforce, contingent on achieving profitability and cash flow from EXUA sales [13][22] Financial Performance - Net revenue for the quarter was $15.2 million, down from $16.2 million in the prior year, with ADHD portfolio revenue at $13.2 million compared to $13.8 million [18] - Gross margin decreased to 63.5% due to transition-related expenses, but would have been 67.4% excluding a $600,000 inventory write-down [13][18] - The company reported a net loss of $10.6 million or $1.05 per share, compared to a net income of $0.8 million or $0.13 per share in the prior year [18] Product Launch and Strategy - EXUA was launched with early prescriptions written in 27 states, and over 100 doctors have prescribed it within the first month [12][19] - The RX Connect platform is designed to minimize administrative burdens for patients and prescribers, ensuring predictable coverage for commercially insured patients [13][19] - The marketing strategy includes a mix of personal and non-personal approaches, focusing on high-volume antidepressant prescribers and leveraging insights from the RX Connect platform [19][23] Market Context - Major depressive disorder affects an estimated 21 million US adults, with a significant portion of patients failing to achieve remission with traditional SSRIs and SNRIs [16][19] - The ADHD portfolio continues to perform above expectations despite a slight revenue decrease, attributed to a strategic shift towards EXUA [18][19] - The company has $30 million in cash and cash equivalents, with ongoing investments focused on EXUA's launch [14][18]